Conclusion: In this systematic review and meta-analysis, there was a trend toward improvement in overall response with VSL#3, but no clear evidence effectiveness for IBS. However, the number and sample sizes of the trials are small and the overall quality of evidence for 3 of the 5 outcomes was low. Larger trials evaluating validated endpoints in well-defined IBS patients are warranted.
Does Vsl#3 help with digestion?
Possibly — but there are few reports. 100% of 5 people who reported on Vsl#3 for digestion say it improved. 0% noticed no change and 0% say it got worse.
People it helped with digestion
“I started taking VSL#3 couple of weeks ago... there's been a mild, but perceptible increase in just overall 'getting things done'.”
“As a sufferer of Ulcerative Colitis, I can say that VSL#3 probiotic has done wonders for me.”
What the research says
Conclusion: Phase IIA studies that incorporate clinical and PD endpoints are feasible in lower FGID associated with constipation or diarrhea. Crossover design would require lower sample size for most endpoints compared to parallel-group studies.
Conclusion: Efficacy and safety of other strains or beneficial effects in other conditions still need to be proven, as probiotic properties are strain-specific, and data cannot be extrapolated to other brain-gut or mood diseases or to other probiotics of the same or different species. To transform the use of probiotics from a tempting suggestion to a promising treatment modality in neurogastroenterological disorders more accurate differentiation of the efficacy-proven strains, clarification of dose, duration, and outcome and a careful selection of the target patients are still necessary.
Based on few reports — treat as anecdotal. Information only — not medical advice. How we count